Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

NCT05378204 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT05378204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05378204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Lead sponsor
Institut Claudius Regaud
Phase
Not applicable
Overall status
Recruiting
Start date
June 23, 2022
Completion date
June 30, 2027
Enrollment
120 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer